The development of the coronary stent market is dependent on the number of people with Coronary Artery Disease (CAD) requiring treatment. The number of Percutaneous Coronary Interventions (PCI) procedures performed, the percentage of PCIs in which stents are used, the number of stents used in each procedure and average selling prices for stents all influence market values. In addition, whether a Bare Metal Stent (BMS) or Drug-Eluting Stent (DES) is used in the procedure impacts the market, as DESs command a much higher selling price than BMSs, while increased competition in the DES market has a major impact on the price companies can command for their DES products.
There are currently over 60 companies active in the coronary stent market, including 30 that offer DES products. However, four companies dominate this industry: Abbott, Boston Scientific, Cordis (part of Johnson & Johnson) and Medtronic. In addition, these companies are the only four to have DESs available in Japan or the US. These products are Abbott’s Xience everolimus-eluting stents, Boston Scientific’s Taxus paclitaxel-eluting stents, Cordis’ Cypher sirolimus-eluting stents and Medtronic’s Endeavor zotarolimus-eluting stents. Abbott’s Xience V DES is also offered as a private-label version by Boston Scientific, which markets the product as the Promus DES. Taking into account combined sales of Xience V and Promus, this product is the world’s best selling DES. Abbott is also global market leader for BMS products with its Multi-Link products.
The coronary stent sector was knocked back when, in 2006, there emerged safety fears regarding the use of the products when some longer-term clinical data indicated there was a small risk of late stent thrombosis for DES patients. It is believed this risk of late stent thrombosis relates to the use of a polymer on the DES and potentially the doses of drug used, both of which impair re-endothelialisation. While endothelialisation can take place within two months for a BMS, it can take up to a year for this process to be completed when a DES is used.
...Looking to a new generation of technology
The industry has responded with a range of new approaches, and the next-generation technologies have received much interest from the medical community due to their potential to address the problems of current coronary stents. These products would also be able to command a higher selling price than current stents and competition for the products would initially be limited. However, as relatively new products with little clinical and longer-term safety data, their potential for success cannot be assured. It therefore remains to be seen if they can reinvigorate the market for coronary stents and provide an effective alternative to current products.
The full,in-depth report was written by Joanne Maddox, a senior medical market analyst for Espicom Business Intelligence. If you would like to read more on the development into the Coronary Stent Market, to see what is included in the full report, or to purchase this detailed analysis, please follow our link below:
Posts
Loving the blog Paul!
ReplyDeleteMany thanks for that Dan!
ReplyDeletePaul